Business Context and Reporting Period
Charles River Laboratories International, Inc. filed a Form 8-K on February 25, 2026, announcing two definitive agreements to divest specific business units. The Company plans to sell its Contract Development and Manufacturing (CDMO) and Cell Solutions businesses to GI Partners and certain European Discovery Services assets to IQVIA Holdings Inc. Both transactions are expected to close in the second quarter of 2026.
Key Financial Metrics and Transaction Details
- CDMO and Cell Solutions Divestiture:
- Revenue Impact: $143 million in 2025 annual revenue ($117 million from Manufacturing Solutions; $26 million from Research Models and Services).
- Consideration: Primarily future, contingent performance-based payments.
- Assets: Sites in Tennessee, Maryland, United Kingdom, and California.
- European Discovery Services Divestiture:
- Revenue Impact: $144 million in 2025 annual revenue (Discovery and Safety Assessment segment).
- Consideration: Approximately $145 million in cash, plus potential additional payments up to $10 million.
- Assets: Five European sites including capabilities in medicinal chemistry, structural biology, and pharmacology.
- Remaining Operations: The Company will retain approximately 40% of its 2025 Discovery Services revenue.
Material Changes and Guidance Updates
The Company updated its 2026 financial guidance to reflect the impact of the planned divestitures, assuming closure in Q2 2026.
| Metric | Prior Guidance | Updated Guidance (Including Divestitures) |
|---|---|---|
| Reported Revenue Growth | At Least Flat to +1.5% | (5.0)% to (3.5)% |
| Organic Revenue Growth | (1.0)% to At Least Flat | (1.5)% to (0.5)% |
| Non-GAAP EPS | $10.70 - $11.20 | $10.80 - $11.30 |
Key Impacts:
- Reported revenue is expected to decrease by slightly more than $200 million in 2026.
- Organic revenue growth guidance is reduced by more than 50 basis points.
- Non-GAAP operating margin is expected to improve by at least 100 basis points.
- Non-GAAP EPS is accretive by approximately $0.10 for the partial year.
Risks, Contingencies, and Management Commentary
- Closing Conditions: Both transactions are subject to customary closing conditions and are not guaranteed to close.
- Non-GAAP Reconciliation: The filing does not provide a reconciliation to GAAP measures because divestiture-related costs (transaction, advisory, transition) are dependent on future events and cannot be reliably predicted.
- Forward-Looking Statements: The guidance relies on assumptions regarding the timing and completion of the divestitures. Actual results may differ materially due to risks outlined in the Company's 2025 Form 10-K.
Investor Verification Checklist
- Verify the final closing dates of the GI Partners and IQVIA transactions to confirm Q2 2026 timing.
- Monitor the actual cash proceeds received from the IQVIA deal versus the estimated $145 million.
- Review future filings for the finalization of divestiture-related costs excluded from non-GAAP EPS.
- Assess the impact of the revenue reduction on the Company's ability to meet long-term strategic goals.
- Confirm the specific terms of the contingent performance-based payments for the CDMO and Cell Solutions sale.